Search results for: Chronic Diseases
Filter search results
Two numbers, one decision: making climate-health valuation usable across sectors
18 May 2026
…Hammitt (2020), whether a value derived from marginal acute risk transfers cleanly to chronic, systemic mortality is unresolved. VSL scales with income. Transferring high-income estimates across borders implicitly assigns a…
OHE Lunchtime Seminar: Health Technology Assessment Scientific and Outcomes Advice on Medicinal Drug Development
4 October 2016, 11:00pm
…faces new challenges with the development of advanced therapy medicinal products, stratified medicines and medicines used in orphan diseases. The role of outcomes advice in HTA is not well understood,…
Disease severity and public preferences
4 November 2010
…preferences for allocating more resources to severe diseases when improvement is likely to be modest. Allocating limited health care resources is a continuing challenge. Maximizing the overall health benefit realized…
Antibacterials: Roundtable Addresses the Critical Issues
10 November 2011
Antibacterial drug resistance is a serious and growing worldwide problem that threatens our ability to cure traditionally treatable diseases and to successfully perform numerous surgical procedures that rely on antibacterials….
New Seminar Briefing: Is Pharmaceutical R&D Experiencing a Productivity Crisis?
14 June 2012
…Riccaboni: The “fishing-out effect” means that the “easy” diseases have been addressed and today’s more complicated targets carry a higher risk of failure The pharmaceutical industry is experiencing a “gestation…
New Pilot Study: Capturing Public Preferences about Health Care Priorities
16 January 2013
…diseases – i.e. those that are most severe or are associated with the greatest unmet need. The DH’s VBP consultation document defines unmet need in terms of the degree to…
Spotlight on OHE: Innovation, Regulation and Antibiotics
30 September 2014
…the extensive resources necessary to develop new treatments in some disease areas, such as orphan diseases, and some therapeutic areas, such as antibiotics. For orphan diseases and antibiotics in particular, one…
OHE at ISPOR Philadelphia: Presentations and Posters
4 June 2015
…large prevalence diseases? Lessons from hepatitis C – Adrian Towse’s slides Early access to medicines: What is in it for payers? – Adrian Towse’s slides An Analysis of NICE ‘Recommended…
As UN General Assembly Highlights Tuberculosis Fight, Will BRICS Lead on the R&D Agenda?
26 September 2018
…donor-driven innovation and market-led R&D. Donors are understandably hesitant to continue bankrolling R&D funding for diseases that mostly affect BRICS; economic growth is already creating fiscal space to drive higher…